A deep learning-based self-adapting ensemble method for segmentation in gynecological brachytherapy

Zhen Li
Shanghai Sixth People's Hospital

Qingyuan Zhu
Shanghai Sixth People's Hospital

Lihua Zhang
Shanghai Sixth People's Hospital

Xiaojing Yang
Shanghai Sixth People's Hospital

Zhaobin Li
Shanghai Sixth People's Hospital

Jie Fu (✉ fujie74@sjtu.edu.cn)
Shanghai Sixth People's Hospital

Research Article

Keywords: deep learning, high-dose-rate brachytherapy, auto-segmentation, gynecological cancer

Posted Date: March 31st, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1485547/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Purpose:

Fast and accurate outlining of the organs at risk (OARs) and high-risk clinical tumor volume (HRCTV) is especially important in high-dose-rate brachytherapy (HDR-BT) due to the highly time-intensive online treatment planning process and the high dose gradient around the HRCTV. This study aims to apply a self-configured ensemble method for fast and reproducible auto-segmentation of OARs and HRCTVs in gynecological cancer.

Materials and methods:

We applied nnU-Net (no new U-Net), an automatically adapted deep convolutional neural network based on U-Net, to segment the OARs and HRCTV in gynecological cancer. In nnU-Net, three architectures, including 2D U-Net, 3D U-Net and 3D-Cascade U-Net, were trained and finally ensembled. 207 cases were randomly chosen for training, and 30 for testing. Quantitative evaluation used well-established image segmentation metrics, including Dice Similarity Coefficient (DSC), 95% Hausdorff distance (HD95%), and Average Surface Distance (ASD). Qualitative analysis of automated segmentation results was performed visually by two radiation oncologists. Dosimetric evaluation was performed by comparing the dose-volume parameters of both predicted segmentation and human contouring.

Results:

nnU-Net obtained high qualitative and quantitative segmentation accuracy on the test dataset, and performed better than previously reported methods in the bladder and rectum segmentation. In quantitative evaluation, 3D-Cascade achieved the best performance in the bladder (DSC: 0.936±0.051, HD95%: 3.503±1.956, ASD: 0.944±0.503), rectum (DSC: 0.831±0.074, HD95%: 7.579±5.857, ASD: 3.6±3.485), and HRCTV (DSC: 0.836±0.07, HD95%: 7.42±5.023, ASD: 2.094±1.311). According to the qualitative evaluation, over 90% of the test data set had no or minor visually detectable errors in segmentation.

Conclusion:

This work demonstrated nnU-Net's superiority in segmenting OARs and HRCTV in gynecological brachytherapy, among which 3D-Cascade shows the highest accuracy in segmentation across different applicators and patient anatomy.

Introduction

The combination of external beam radiation therapy (EBRT) and HDR-BT is a standard care for treatment in gynecological cancers\cite{1,2}, in which HDR-BT has proven to be indispensable and has a strong correlation with a higher survival rate\cite{2–4}.
In the HDR-BT treatment, contouring of OARs and HRCTV should be careful and accurate for better organ sparing and tumor control due to the high dose gradient in brachytherapy. However, unlike heaps of treatment planning time in EBRT, there is limited time for the planning procedure during HDR-BT because the radiation oncologists and medical physicists should finish the contouring in the shortest possible time to reduce the patient’s uncomfortableness and the possibilities of patient movement[5, 6]. It is estimated that a radiation oncologist needs 32 minutes on average to delineate the HRCTV and OARs for gynecologic malignancies[7]. The requirements of fast pace and accurate planning will put the entire workflow under high pressure, thus increasing planning errors. Moreover, the planner’s experience level and preferences would result in significant inter-and intra-observer variations [8, 9], further introducing more uncertainties in treatment planning and dose delivery[10–12].

Therefore, the contouring of OARs and HRCTV in HDR-BT is often considered the bottleneck in the clinical workflow[13, 14]. There is a strong need for a precise and fast automatic contouring tool in the clinic. For a long time, there have been attempts to automate the contouring process. Most of the studies focus on segmentation tools including atlas-based and deep learning methods[15, 16]. In the past ten years, atlas-based auto-segmentation (ABAS) algorithms, which segment the contours based on a library of reference images, mapping elements to the target image using deformable image registration algorithm, are widely used for auto-segmentation. Kim et al. segmented CTV and OARs in endometrial gynecological cancer and achieved the best dice of 0.75 as well as an averaged segmentation time of 45.1s[17]. Although ABAS increases the contouring efficiency, it still has some disadvantages. Kim stated organs isodense with their surroundings are not suitable subjects for ABAS. Teguh et al. found ABAS does not perform well for small and thin OARs[18]. Moreover, it is reported that approximately 5000 atlases should be included to achieve a segmentation level corresponding to clinical quality[19]. However, even for those studies using large databases, the atlas selection may be unreliable, potentially influencing the segmentation performance[20]. Finally, applicators and CT markers may bring metal artifacts to the CT images and degrade the image quality, which causes an undesirable effect on the segmentation [21]. Thus, the ABAS method does not have many clinical applications because this approach is limited in accuracy, thereby leading to slight improvement at best, in contouring efficiency.

With the increasing popularity of deep learning, multiple architectures have been developed and applied in medical image segmentation, such as Cascaded U-Net[22–24], VGGNet[25], AlexNet[26, 27], DenseNet[28, 29], ResNet[30, 31], some of these methods have achieved good results and outperformed the ABAS for the majority of clinical cases[32–35]. Despite the good performance achieved by these networks, their applicability to specific image segmentation is often limited. The task-specific design and configuration of a network require careful fine-tuning. Slight variations in hyperparameters could lead to large differences in performance. A fine-tuned neural network model for one specific task is highly possible to fail in other application scenarios[36].

nnU-Net is the first fully automatic framework for biomedical segmentation. It consists of 2D, 3D and 3D Cascade U-Net based on several convolution and deconvolution layers, with skip connections[37]. The most attracting part of nn U-net is the automatic configuration of the pre- and post-processing, network
architecture, and training for any new task. This robust strategy outperforms even highly specialized solutions on 23 public datasets used in international biomedical segmentation competitions[38]. Similar standardized schemes based on self-adapted architecture have not been applied in gynecological cancer and HDR brachytherapy treatment. In this work, nnU-Net is proposed for gynecological cancer patients in HDR-BT. It has proved to have better segmentation accuracy than existing methods and can be easily translated to clinical practice.

**Methods And Materials**

### 2.1 Patient selection and contouring

62 patients were included in the retrospective study approved by the institutional review board. Each patient contains 2–6 fractions; and each fraction has a unique CT structure set. A total of 237 cases were included in this study. 207 cases were used for training and 30 cases for testing. A “case” in this context indicates one single fraction in the treatment. These patients were randomly selected from the gynecological patients between January 2019 and September 2021. All the CT images were acquired using 120kV and 60mAs at a GE 128 slice CT (Discovery, GE Healthcare, Inc.). The slice thickness and slice increment were 2.5*2.5mm; and the image resolution was 512*512. All the scans used same image acquisition and reconstruction protocol. Each patient was treated with an applicator set among Tandem and Ovoid applicator (T + O), Vaginal Multi-Channel applicator, Ovoid applicator, free needles, and a tandem applicator with up to 10 interstitial needles (T + N) (see supplemental material, Table 1). The HRCTV and OARs were manually delineated using the Oncentra System (Elekta, Stockholm, Sweden) by an experienced radiation oncologist. All the contours were reviewed and edited by another more experienced radiation oncologist. The results confirmed by the second oncologist were considered the final delineations (i.e., the ground truth) for training and testing.

### 2.2 Geometric Evaluation

#### 2.2.1 Quantitative Evaluation

To evaluate the performance of the predicted results, we compared its segmentation with the provided ground truth. We used the Dice Similarity Coefficient (DSC)[39], Average Surface Distance (ASD), and 95% Hausdorff Distance (HD95%)[40] as three indicators to evaluate the accuracy of segmentation. These indicators are the most widely used metrics for quantitatively assessing segmentation quality in auto-segmentation.

#### 2.2.2 Qualitative Evaluation

Two radiation oncologists (5-year and 20-year clinical experience) evaluated the auto-segmentation results visually and graded the results using a 4-point Likert scale[41], in which Point 1 indicates no visible segmentation errors; Point 2 indicates minor segmentation errors; Point 3 indicates major segmentation errors; Point 4 indicates failed segmentation/ no segmentation.
2.3 Dosimetric Evaluation

Dosimetric evaluation was performed to illustrate the difference in OARs and HRCTV between predicted segmentation and human contouring. Standard deviation over the residuals was considered as a measure of model error. The prescription dose was 5-6Gy in each fraction and each patient contained 2–6 fractions. Plans were created considering the external beam and BT equivalent dose in 2 Gy fractions (EQD2). The OAR dose constraints and the prescription dose were based on American Brachytherapy Society HDR-BT guidelines for locally advanced gynecological cancer [42] and later updated EMBRACE-II trial[43]. For HRCTV, D_{90\%} (the minimum dose given to 90\% of the target volume), and V_{100\%}, V_{150\%}, V_{200\%} (the target volume enveloped by 100\%, 150\% and 200\% of the prescribed dose) were evaluated. For OARs, the minimum dose received by 2cm^3, 1cm^3, 0.1cm^3 (D_{2cc}, D_{1cc}, D_{0.1cc}), and the maximum dose (D_{max}), were evaluated. Since the dose distribution, and by extension, dose-volume parameters, can vary largely between different plans, a customized python program was developed to calculate the dose-volume parameters based on predicted contours (P_{predicted}) using the dose map of original plan created based on manual contours (P_{original}). Namely, the P_{predicted} and P_{original} shared the same dose map, simulating the same applicator position, source dwell position and dwell time. Model performance was quantified by calculating the residual of dose-volume parameters between P_{predicted} and P_{original}.

2.4 Auto-segmentation Network

In this study, nnU-Net was selected to provide a standardized workflow to achieve accurate and reproducible segmentation. The program was implemented with Python 3.7, and performed on a workstation platform with an NVIDIA GeForce RTX 3060 GPU in an Ubuntu 20.04.3 operating system.

2.4.1 Network Architecture and Training Workflow

The architecture template of nnU-net is a ‘U-Net-like’ encode-decoder with skip connections and instance normalization. It provides three architectures based on the U-Net backbone: a two-dimensional (2D) U-Net, a three-dimensional (3D) U-Net training all images at full image resolution (3D-Fullres), and a 3D U-Net cascade network (3D-Cascade). The 3D-Cascade network contains two U-Nets, the first 3D U-Net creates coarse segmentation maps on down-sampled images (3D-Lowres); and the second 3D U-Net operates on full resolution images to refine the segmentation map created by the first one. In ensemble, nnU-Net empirically chooses the best model (or combination of two) from 2D U-Net, 3D-Fullres or 3D-Cascade according to the five-fold cross-validation results. Networks are ensembled by averaging softmax probabilities. After training, the post-processing is triggered for individual classes by removing all small holes inside the OARs and HRCTV.

2.4.2 Hyperparameter Setting

The data augmentation methods include scaling, rotation, adding Gaussian blur and Gaussian noise, simulating low-resolution gamma mirroring, and Gamma augmentation. Each architecture went through five-fold cross-validation and each fold ran for 1000 epochs with an epoch size of 250. The optimizer
used stochastic gradient descent with a high initial learning rate (0.01) and a large momentum ($\mu = 0.99$). We adapted 'poly' learning rate decay strategy $(1 - \text{epoch}/\text{epoch}_{\text{max}})^{0.9}$ to accelerate convergence. The activate function was leaky ReLU. To improve the training stability and segmentation accuracy, nnU-Net used a combination of dice and cross-entropy as loss function empirically. The batch and patch size are shown in Table 1.

Table 1
The batch size and patch size for each network were adjusted according to the image size and GPU’s computing power.

|                | 2D          | 3D-Fullres  | 3D-Lowres   |
|----------------|-------------|-------------|-------------|
| Median Image Size | 63×512×512  | 63×512×512  | 63×354×354  |
| Median Target Spacing | 2.5×0.75×0.75 | 2.5×0.75×0.75 | 2.5×1.0838×1.0838 |
| Patch Size      | NA×512×512  | 28×256×256  | 40×224×224  |
| Batch Size      | 12          | 2           | 2           |

2.5 Statistical Analysis

We considered possible variables that could potentially explain the variance of auto-segmentation quality through ANOVA (analysis of variance). The independent variables are applicator type, organ type, and tumor location (vagina, uterus, or both). The dependent variables are DSC values in geometric evaluation. Moreover, Cohen's kappa ($\kappa$) evaluated the inter-observer agreement between the two radiation oncologists at qualitative evaluation. To test for significant differences ($p < 0.05$) between the three architectures' performance, we used an independent two-sample t-test as calculated with SciPy for OARs and HRCTV.

Results

3.1 Geometric Evaluation

3.1.1 Quantitative Evaluation

All three architectures successfully segmented the bladder, rectum and HRCTV on the test dataset. The performance for each metric is shown in Table 2. A general trend in the test dataset showed that the DSC in order from highest to lowest was the bladder, rectum and HRCTV, and DSC values in rectum and HRCTV were almost identical. A similar trend was observed in the ASD and HD95%, in which bladder achieved the highest performance and rectum has a comparable performance with HRCTV.

The highest DSC, of any network, in the evaluation dataset as compared to manual segmentations (i.e., ground truth) for each contouring were $0.936 \pm 0.051$ (bladder in 3D-Cascade), $0.831 \pm 0.074$ (rectum in 3D-Cascade), and $0.836 \pm 0.07$ (HRCTV in 3D-Cascade). The lowest HD95%, of any network, were $3.495 \pm$
2.291 (bladder in 3D-Fullres), 7.579 ± 5.857 (rectum in 3D-Cascade), and 7.42 ± 5.023 (HRCTV in 3D-Cascade). The lowest ASD, of any network, were 0.944 ± 0.503 (bladder in 3D-Cascade), 3.6 ± 3.485 (rectum in 3D-Cascade), and 2.094 ± 1.311 (HRCTV in 3D-Cascade).

### Table 2
Auto-segmentation network performance compared to manual segmentation (i.e., ground truth) on bladder, rectum, and HRCTV for each metric.

| Model      | DSC      | HD95%     | ASD       |
|------------|----------|-----------|-----------|
| **Bladder**|          |           |           |
| 2D         | 0.917 ± 0.054 | 4.381 ± 2.5 | 1.372 ± 1.073 |
| 3D-Fullres | 0.935 ± 0.05  | 3.495 ± 2.291 | 0.95 ± 0.56     |
| 3D-Cascade | 0.936 ± 0.051 | 3.503 ± 1.956 | 0.944 ± 0.503   |
| Ensemble   | 0.935 ± 0.05  | 3.495 ± 2.291 | 0.95 ± 0.56     |
| **Rectum** |          |           |           |
| 2D         | 0.808 ± 0.106 | 9.97 ± 8.267 | 3.949 ± 4.178   |
| 3D-Fullres | 0.816 ± 0.098 | 8.137 ± 7.581 | 3.719 ± 3.084   |
| 3D-Cascade | 0.831 ± 0.074 | 7.579 ± 5.857 | 3.6 ± 3.485     |
| Ensemble   | 0.831 ± 0.074 | 7.579 ± 5.857 | 3.6 ± 3.485     |
| **HRCTV**  |          |           |           |
| 2D         | 0.763 ± 0.136 | 9.186 ± 5.347 | 2.718 ± 1.631   |
| 3D-Fullres | 0.806 ± 0.108 | 8.815 ± 6.485 | 2.46 ± 1.756    |
| 3D-Cascade | 0.836 ± 0.07  | 7.42 ± 5.023  | 2.094 ± 1.311   |
| Ensemble   | 0.806 ± 0.108 | 8.815 ± 6.485 | 2.46 ± 1.756    |

### 3.1.2 Network Architecture Comparison

Figure 2 shows a comparison of auto-segmentation performance for the 2D, 3D-Fullres, 3D-Cascade, and Ensemble. In general, 3D networks perform better than 2D for all evaluation metrics. The addition of low-resolution network in 3D-Cascade has relatively improved performance compared with 3D-Fullres, with slightly higher DSC, lower ASD, and HD 95%. For bladder and HRCTV, ensemble results were identical with 3D-Fullres because 3D-Fullres has the highest performance during cross-validation, while 3D-Cascade performs the best for rectum in cross-validation.

The auto-segmentation results of each network architecture are shown in Fig. 3. All three networks have a good segmentation for OARs and HRCTV.

### 3.1.3 Qualitative Evaluation
In general, qualitative evaluation of the segmentation performance revealed high accuracy for all the OARs and HRCTV in 2D, 3D-Fullres, 3D-Cascade networks, and ensemble results. Most of the data has no obvious segmentation errors, with at least 73% (HRCTV in 2D network) of the evaluation data achieving point 1. Errors of the second level (minor segmentation errors) were observed at the top slice in rectum. Third level (major segmentation errors) were noticed only in a few single cases in which abnormal anatomy (e.g., large air bubbles in the bladder) exists. Compared with bladder and rectum, HRCTV segmentations showed a marginally higher rate of minor errors (point 2). Failed segmentation only occurred in one case because the contrast enhanced agent resided in the bladder (See supplemental material, Fig. 1). Overall, the bladder segmentation showed the best qualitative results compared with the rectum and HRCTV. Figure 4 demonstrates the qualitative segmentation results. Good interobserver agreement was achieved on 2D ($\kappa = 0.67$), 3D-Fullres ($\kappa = 0.69$), 3D-Cascade ($\kappa = 0.78$) and ensemble ($\kappa = 0.71$) segmentations.

### 3.2 Dosimetric Evaluation

To evaluate the dosimetric accuracy, we compared the dose-volume parameters obtained from predicted contours with manually delineated contours (Table 3). The prescription dose given to the patients were 6Gy (15 cases), 5.5Gy (6 cases) and 5Gy (9 cases). The average difference for $\triangle D_{90\%}$ in HRCTV is $0.46 \pm 1.2$, $0.43 \pm 0.34$, and $0.21 \pm 0.53$ for the prescription dose of 6Gy, 5.5Gy, 5Gy, respectively. For OARs, the average difference in $D_{2cc}$ is smaller than 15%.

|                | HRCTV       | Bladder     | Rectum     |
|----------------|-------------|-------------|------------|
| **Rx = 6**     | **Rx = 5.5**| **Rx = 5**  |            |
| $D_{90\%}$     | 0.46        | 0.43        | 0.21       |
|                | $\pm 1.2$   | $\pm 0.34$  | $\pm 0.53$ |
| $D_{2cc}$      | 0.88        | 0.82        | 0.23       |
|                | $\pm 0.67$  | $\pm 0.06$  | $\pm 0.13$ |
| $D_{1cc}$      | 0.97        | 0.93        | 0.21       |
|                | $\pm 0.72$  | $\pm 0.08$  | $\pm 0.02$ |
| $D_{0.1cc}$    | 1.22        | 1.06        | 0.18       |
|                | $\pm 0.98$  | $\pm 0.08$  | $\pm 0.19$ |
| $D_{\max}$    | 1.31        | 1.2         | 0.1        |
|                | $\pm 1.29$  | $\pm 0.3$   | $\pm 0.23$ |
| $D_{max}$      | 0.95        | 0.42        | 0.29       |
|                | $\pm 1.5$   | $\pm 1.06$  | $\pm 0.24$ |

*Rx is the prescription dose. The unit is Gy for $D_{90\%}$, $D_{2cc}$, $D_{1cc}$, $D_{0.1cc}$ and $D_{\max}$, and cc for $V_{100\%}$, $V_{150\%}$, and $V_{200\%}$. 

---

Table 3  
Results of dosimetric parameters for bladder, rectum and HRCTV. All values are described in the form of mean ± standard deviation.
3.3 Analysis of Factors Affecting Auto-segmentation Accuracy

Analysis of variance demonstrated that the applicator type and the organ type were statistically significant factors affecting segmentation results. DSC was statistically significantly better for Vaginal Multi-Channel applicator and Ovoids applicator compared with T + N, T + O, and free needles (p < 0.05), and for the bladder compared with rectum and HRCTV (p < 0.05). Tumor location had no statistically significant effect on the segmentation results.

Discussion

Auto-segmentation is highly desired in brachytherapy treatment planning since patients could hardly hold on to one position for a long time. Moreover, minimizing the HRCTV and OARs contouring variability can improve the consistency of plan quality, and thus allows dose-escalation strategy in HRCTV. This study sets out to employ nn U-net, a self-adapting ensemble method for simultaneous multi-organ contouring in gynecological brachytherapy. We showed that this method offers us a standardized workflow for auto-segmentation and achieved fairly good results compared with the manual contour.

The nnU-net method has three architectures followed with an ensemble method to select the best architecture for each task. In general, 3D architecture out-performed 2D slightly and reached competitive quantitative performance with DSC values well above 0.8. The performances of deep learning-based auto-contouring in gynecological cancer from other published papers are shown in Table 4. Two brachytherapy studies and two external-beam radiation therapy studies were included for reference. In comparison with previous studies, our method has the highest performance in bladder and rectum segmentation, concerning a DSC of 0.936 ± 0.051 for bladder and 0.831 ± 0.074 for the rectum. The DSC of automated HRCTV segmentation (0.836 ± 0.07) was slightly inferior compared with the EBRT study[44] (0.86 ± 0.02) and Rhee's BT study (0.86 ± 0.08)[45]. The complex shape can explain this and different applicators used in BT compared with EBRT cases and the large data set used in Rhee's BT study. Overall, as far as directly comparable, the observed DSC value of automated segmentation in our study was competitive compared with similar previous research. The possible reason may be the larger training data set in this study (more than 200 training cases), which has more anatomical variability and applicator types than similar studies using a small dataset.
Table 4  
Summary of deep learning-based auto-segmentation results in gynecological cancer from other groups.

| Publication                  | Data Type | Training Cases | Testing Cases | Method      | Organ     | DSC       |
|------------------------------|-----------|----------------|---------------|-------------|-----------|-----------|
| Zhang et al. (2020)[46]      | BT        | 73             | 18            | DSD-UNET    | Bladder   | 0.869 ± 0.032 |
|                              |           |                |               |             | Rectum    | 0.821 ± 0.05  |
|                              |           |                |               |             | HRCTV     | 0.829 ± 0.041 |
|                              |           |                |               | 3D-UNET     | Bladder   | 0.802 ± 0.041 |
|                              |           |                |               |             | Rectum    | 0.771 ± 0.062 |
|                              |           |                |               |             | HRCTV     | 0.742 ± 0.062 |
| Wang et al. (2020) [44]      | EBRT      | 100            | 25            | 3D-CNN      | Bladder   | 0.91 ± 0.06   |
|                              |           |                |               |             | Rectum    | 0.81 ± 0.04   |
|                              |           |                |               |             | HRCTV     | 0.86 ± 0.02   |
| Liu et al. (2020) [47]       | EBRT      | 77             | 14            | Improved UNET | Bladder   | 0.924 ± 0.046 |
|                              |           |                |               |             | Rectum    | 0.791 ± 0.032 |
| Rhee et al. (2020) [45]      | BT        | 2254           | 140           | CNN         | Bladder   | 0.89 ± 0.09   |
|                              |           |                |               |             | Rectum    | 0.81 ± 0.09   |
|                              |           |                |               |             | HRCTV     | 0.86 ± 0.08   |
| Our Method                   | BT        | 205            | 30            | nnU-NET     | Bladder   | 0.936 ± 0.051 |
|                              |           |                |               |             | Rectum    | 0.831 ± 0.074 |

Note: If multiple network architectures are reported in the literature, the best-performing result was selected. The highest performance results (3D-Cascade) in our study were used for comparison. DSD-UNET: 3D-UNET incorporating residual connection, dilated convolution, and deep supervision.
Generally, bladder has the best performance with an average DSC of 0.936 ± 0.051. The reason could be the significantly different CT values in bladder compared with other organs in the pelvis. The architecture did not significantly differ between 2D and 3D in bladder and rectum; the main reason for this could be the non-progressive change between different slices, especially at the upper part of the rectum and the lower part of the bladder. According to our ANOVA test, the factors affecting the segmentation accuracy include the applicator type and organ type. HRCTV contouring has higher performance in the vaginal applicator and ovoid applicator. The possible reason could be less metal artifact in the vaginal and ovoid applicator. In addition, the segmentation accuracy did not significantly differ among different tumor locations.

| Publication | Data Type | Training Cases | Testing Cases | Method | Organ | DSC       |
|-------------|-----------|----------------|---------------|--------|-------|-----------|
|             |           |                |               |        | HRCTV | 0.836 ± 0.07 |

Note: If multiple network architectures are reported in the literature, the best-performing result was selected. The highest performance results (3D-Cascade) in our study were used for comparison. DSD-UNET: 3D-UNET incorporating residual connection, dilated convolution, and deep supervision.

Based on these results, we feel it possible to integrate these trained models in clinical workflow under staff supervision to solve the tricky problems in gynecological brachytherapy. However, the total time required for prediction is relatively long, taking on an average of 2.7 minutes (2D), 14 minutes (3D-Fullres network), 16 minutes (3D-Cascade network), and 18.5mins (Ensemble) at an NVIDIA GeForce RTX 3060 GPU setting (Table 5). Ensemble has the longest prediction time because the contours in ensemble are generated using all the five-fold images aggregated by softmax and the prediction time increased rapidly with network architecture complexity. Thus, we also calculate the prediction time in a single fold (fold 0) and compare it with the prediction time of all five folds. The prediction time for one single fold vastly decreased to one-fifth of the five folds. Using the well-trained one-fold model in the clinic can improve the
prediction efficiency. As shown in Table 6, the corresponding prediction accuracy of one-fold is slightly worse than five folds. This requires clinical users to make trade-offs between predicting accuracy and efficiency. Another possible solution could be using a more powerful graphic unit to increase the calculation speed. Further work related to architecture improvement or compression to accelerate the prediction speed is also a good research orientation.

| Model      | DSC-fold0 | DSC-5folds |
|------------|-----------|------------|
| **Bladder**|           |            |
| 2D         | 0.902 ± 0.084 | 0.917 ± 0.054 |
| 3D-Fullres | 0.917 ± 0.231 | 0.935 ± 0.05 |
| 3D-Cascade | 0.908 ± 0.045 | 0.936 ± 0.051 |
| Ensemble   | ___        | 0.935 ± 0.05 |
| **Rectum** |           |            |
| 2D         | 0.795 ± 0.115 | 0.808 ± 0.106 |
| 3D-Fullres | 0.805 ± 0.152 | 0.816 ± 0.098 |
| 3D-Cascade | 0.820 ± 0.131 | 0.831 ± 0.074 |
| Ensemble   | ___        | 0.831 ± 0.074 |
| **HRCTV**  |           |            |
| 2D         | 0.741 ± 0.112 | 0.763 ± 0.136 |
| 3D-Fullres | 0.780 ± 0.091 | 0.806 ± 0.108 |
| 3D-Cascade | 0.813 ± 0.102 | 0.836 ± 0.07 |
| Ensemble   | ___        | 0.806 ± 0.108 |

In deep learning-based image segmentation area, lots of novel architectures are proposed in organ segmentation. However, fine-tuning of the hyper-parameters is tedious and time-consuming. Moreover, the generalizability and feasibility of clinical application needs further validation. In this study, we use nn U-net, a self-configuring and fully automated framework with a robust training strategy for segmentation. It systematizes the complex process of manual configuration instead of proposing a new network architecture, loss function or training scheme and achieved fairly good results[38]. In the future, we are going to extend the application of nn U-net to other medical image segmentation areas.

**Conclusion**

In this work, we have demonstrated that it is feasible to use a standardized nnU-net method for OARs and HRCTV segmentation in gynecological cancer. The results show that combining a low-resolution and high-resolution U-net (3D-Cascade) has the highest accuracy in segmentation. With this 3D-Cascade network, high segmentation accuracy was obtained across different applicators and patient anatomy.
Such performance would be beneficial to the clinical workflow by reducing the interobserver variations, releasing radiation oncologists’ and physicists’ burden, reducing patients’ pain, and increasing the planning efficiency in gynecological cancer treatment to a large extent.

**Abbreviations**

- OAR: Organs at Risk
- HRCTV: High-risk Clinical Tumor Volume
- HDR-BT: High-Dose-rate Brachytherapy
- DSC: Dice Similarity Coefficient
- HD95%: 95% Hausdorff distance
- ASD: Average Surface Distance
- EBRT: external beam radiation therapy
- ABAS: atlas-based auto-segmentation
- T+O: Tandem and Ovoid applicator
- T+N: Tandem applicator with up to 10 interstitial needles
- ANOVA: analysis of variance

**Declarations**

- **Ethical Approval and Consent to participate**

All the medical images were obtained with the informed consent of all participants. The institutional review board of the Shanghai Sixth People’s Hospital approved the protocol of Deep Learning-based Auto-segmentation of Organs at Risk and Clinical Tumor Volume in Brachytherapy for Cervical Cancer

- **Consent for publication**

Not applicable

- **Availability of supporting data**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

- **Competing interests**
The authors declare that they have no competing interests

• Funding

This work has no funding statement.

• Authors' contributions

Zhen Li was responsible for the coding part and paper writing.

Qingyuan Zhu was responsible for the data acquisition and paper review.

Xiaojing Yang, Lihua Zhang, Zhaobin Li, and Jie Fu were responsible for the image segmentation and evaluation.

Jie Fu and Zhaobin Li designed the project and offered guidance in the study.

• Acknowledgements

Not applicable.

Footnotes

Programming code of nnUnet: https://github.com/MIC-DKFZ/nnUNet.

References

1. Viswanathan, A.N., et al., Increasing brachytherapy dose predicts survival for interstitial and tandem-based radiation for stage IIIB cervical cancer. Int J Gynecol Cancer, 2009. 19(8): p. 1402–6.

2. Tanderup, K., et al., Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys, 2014. 88(3): p. 537–9.

3. Holschneider, C.H., et al., Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS). Brachytherapy, 2019. 18(2): p. 123–132.

4. Rose, P.G., et al., Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 2007. 25(19): p. 2804–10.

5. Mayadev, J., et al., Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy, 2014. 13(3): p. 233–9.

6. Zhou, Y., et al., Automated high-dose rate brachytherapy treatment planning for a single-channel vaginal cylinder applicator. Phys Med Biol, 2017. 62(11): p. 4361–4374.
7. Fujimoto, D.K., et al., *Improving brachytherapy efficiency with dedicated dosimetrist planners.* Brachytherapy, 2019. 18(1): p. 103–107.

8. Jones, M.P., et al., *The impact of contour variation on tumour control probability in anal cancer.* Radiat Oncol, 2018. 13(1): p. 97.

9. Riegel, A.C., et al., *Deformable image registration and interobserver variation in contour propagation for radiation therapy planning.* J Appl Clin Med Phys, 2016. 17(3): p. 347–357.

10. Weiss, E., et al., *Conformal radiotherapy planning of cervix carcinoma: differences in the delineation of the clinical target volume. A comparison between gynaecologic and radiation oncologists.* Radiother Oncol, 2003. 67(1): p. 87–95.

11. Rosa, C., et al., *Volume delineation in cervical Cancer With T2 and diffusion-weighted MRI: agreement on volumes between observers.* in vivo, 2020. 34(4): p. 1981–1986.

12. Bell, L., et al., *Dose planning variations related to delineation variations in MRI-guided brachytherapy for locally advanced cervical cancer.* Brachytherapy, 2020. 19(2): p. 146–153.

13. Ma, C.Y., et al., *Deep learning-based auto-segmentation of clinical target volumes for radiotherapy treatment of cervical cancer.* J Appl Clin Med Phys, 2021.

14. Shi, J., et al., *Automatic clinical target volume delineation for cervical cancer in CT images using deep learning.* Med Phys, 2021. 48(7): p. 3968–3981.

15. Cerrolaza, J.J., et al., *Computational anatomy for multi-organ analysis in medical imaging: A review.* Med Image Anal, 2019. 56: p. 44–67.

16. Lavdas, I., et al., *Fully automatic, multiorgan segmentation in normal whole body magnetic resonance imaging (MRI), using classification forests (CFs), convolutional neural networks (CNNS), and a multi-atlas (MA) approach.* Med Phys, 2017. 44(10): p. 5210–5220.

17. Kim, N., et al., *Atlas-based auto-segmentation for postoperative radiotherapy planning in endometrial and cervical cancers.* Radiat Oncol, 2020. 15(1): p. 106.

18. Teguh, D.N., et al., *Clinical validation of atlas-based auto-segmentation of multiple target volumes and normal tissue (swallowing/mastication) structures in the head and neck.* Int J Radiat Oncol Biol Phys, 2011. 81(4): p. 950–7.

19. Schipaanboord, B., et al., *Can Atlas-Based Auto-Segmentation Ever Be Perfect? Insights From Extreme Value Theory.* IEEE Trans Med Imaging, 2019. 38(1): p. 99–106.

20. Peressutti, D., et al., *TU-AB-202-10: How Effective Are Current Atlas Selection Methods for Atlas-Based Auto-Contouring in Radiotherapy Planning?* Medical physics, 2016. 43(6Part33): p. 3738–3739.

21. Mohammadi, R., et al., *2. Deep learning-based auto-segmentation of organs at risk in high-dose rate brachytherapy of cervical cancer.* Radiother Oncol, 2021. 159: p. 231–240.

22. Roth, H.R., et al., *An application of cascaded 3D fully convolutional networks for medical image segmentation.* Comput Med Imaging Graph, 2018. 66: p. 90–99.
23. Chen, S., et al., *Towards automatic abdominal multi-organ segmentation in dual energy CT using cascaded 3D fully convolutional network.* arXiv preprint arXiv:1710.05379, 2017.

24. Christ, P.F., et al. *Automatic liver and lesion segmentation in CT using cascaded fully convolutional neural networks and 3D conditional random fields.* in *International Conference on Medical Image Computing and Computer-Assisted Intervention.* 2016. Springer.

25. Simonyan, K. and A. Zisserman, *Very deep convolutional networks for large-scale image recognition.* arXiv preprint arXiv:1409.1556, 2014.

26. Krizhevsky, A., I. Sutskever, and G.E. Hinton, *Imagenet classification with deep convolutional neural networks.* Advances in neural information processing systems, 2012. 25: p. 1097–1105.

27. Chen, J., et al., *Medical image segmentation and reconstruction of prostate tumor based on 3D AlexNet.* Comput Methods Programs Biomed, 2021. 200: p. 105878.

28. Huang, G., et al. *Densely connected convolutional networks.* in *Proceedings of the IEEE conference on computer vision and pattern recognition.* 2017.

29. Tao, Z., et al., *NSCR-Based DenseNet for Lung Tumor Recognition Using Chest CT Image.* Biomed Res Int, 2020. 2020: p. 6636321.

30. He, K., et al. *Deep residual learning for image recognition.* in *Proceedings of the IEEE conference on computer vision and pattern recognition.* 2016.

31. Lu, S., S.H. Wang, and Y.D. Zhang, *Detecting pathological brain via ResNet and randomized neural networks.* Heliyon, 2020. 6(12): p. e05625.

32. van Dijk, L.V., et al., *Improving automatic delineation for head and neck organs at risk by Deep Learning Contouring.* Radiotherapy and Oncology, 2020. 142: p. 115–123.

33. Aoyama, T., et al., *Comparison of atlas-based auto-segmentation accuracy for radiotherapy in prostate cancer.* Phys Imaging Radiat Oncol, 2021. 19: p. 126–130.

34. Chen, W., et al., *Deep learning vs. atlas-based models for fast auto-segmentation of the masticatory muscles on head and neck CT images.* Radiat Oncol, 2020. 15(1): p. 176.

35. Lustberg, T., et al., *Clinical evaluation of atlas and deep learning based automatic contouring for lung cancer.* Radiother Oncol, 2018. 126(2): p. 312–317.

36. Huo, L., et al., *Segmentation of whole breast and fibroglandular tissue using nnU-Net in dynamic contrast enhanced MR images.* Magn Reson Imaging, 2021. 82: p. 31–41.

37. Zhou, Z., et al., *Unet++: A nested u-net architecture for medical image segmentation,* in *Deep learning in medical image analysis and multimodal learning for clinical decision support.* 2018, Springer. p. 3–11.

38. Isensee, F., et al., *nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation.* Nat Methods, 2021. 18(2): p. 203–211.

39. Chaganti, S. and B.A. Landman, *QUADRATIC: Quality of Dice in Registration Circuits.* Proc SPIE Int Soc Opt Eng, 2018. 10574.
40. Taha, A.A. and A. Hanbury, *Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool*. BMC Med Imaging, 2015. 15: p. 29.

41. Chabot, J.M., *[Likert's scale: clinical assessment]*. Rev Prat, 2005. 55(10): p. 1111–2.

42. Yamada, Y., et al., *American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy*. Brachytherapy, 2012. 11(1): p. 20–32.

43. Pötter, R., et al., *The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies*. Clin Transl Radiat Oncol, 2018. 9: p. 48–60.

44. Wang, Z., et al., *Evaluation of deep learning-based auto-segmentation algorithms for delineating clinical target volume and organs at risk involving data for 125 cervical cancer patients*. J Appl Clin Med Phys, 2020. 21(12): p. 272–279.

45. Rhee, D.J., et al., *Automatic contouring system for cervical cancer using convolutional neural networks*. Med Phys, 2020. 47(11): p. 5648–5658.

46. Zhang, D., et al., *Automatic segmentation and applicator reconstruction for CT-based brachytherapy of cervical cancer using 3D convolutional neural networks*. J Appl Clin Med Phys, 2020. 21(10): p. 158–169.

47. Liu, Z., et al., *Segmentation of organs-at-risk in cervical cancer CT images with a convolutional neural network*. Phys Med, 2020. 69: p. 184–191.

**Figures**
Figure 1

An overview of training workflow

Figure 2
Comparison of the auto-contouring performance of three network architectures, as assessed with DSC, ASD, and HD95%. Significant differences between 2D, 3D-Fullres, 3D-Cascade and Ensemble are marked with an asterisk *p < 0.05.

Figure 3

Visualization of segmentation in axial, sagittal, and coronal views with manual contouring (solid line) and auto-segmentation (dashed line): rectum (purple), bladder (green), and HRCTV (orange). All three architectures have a good segmentation in cervical cases inserted with different applicators (a. Needles+Tandem Applicator; b. Ovoid Applicator; c. Vaginal Multi-channel Applicator)

![Figure 3](image)

Figure 4

Qualitative segmentation results were evaluated by two radiation oncologists. A stacked bar chart demonstrates the distribution of qualitative evaluation scores (Point 1-Point 4) of three networks and ensemble results. Most segmentations showed no error (Point 1). Single cases showed only minor (Point 2) errors. Only one single case showed failed segmentation due to contrast enhanced agent exists in the bladder (Point 4).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplymentalNotes.docx